The principal objective of the Radiopharmacy and Assays Core (Core B) is to support Project 1: Radioimmunotherapy: Clinical Studies, Project 2: Pretargeting with anti-CEA Antibodies for Therapy, and Project 3: CEA Targeted Immunotherapeutics by providing expertise and facilities to prepare radiolabeled antibodies and quality control for therapeutic and imaging reagents. Yttrium-90 radiolabeled chimeric/humanized T84.66 anti-CEA antibody will be used in the clinical trials for colon and lung cancer satients, and yttrium-90 radiolabeled Herceptin will be used in breast cancer patients at the City of Hope National Medical Center, lndium-111 radiolabeled chimeric/humanized T84.66 antibody, Avastin and Herceptin will be used for imaging and dosimetry studies. The radiopharmacy will support Project 1 by providing the radiolabeled antibodies and will provide quality control for these reagents. This Core is also responsible for the analysis of patient (and animal) blood samples to evaluate the blood clearance and stability of the administered products. Patient sera samples are also analyzed to monitor the patient's immune response to the injected antibody constructs. Core B also performs the radiolabeling of all the antibodies, engineered antibodies, chemically modified antibodies and haptens for preclinical in vitro and in vivo use. Procedures involved in preparation of the radiopharmaceutical agents include chelate conjugate chemistry and conjugation as well as the antibody radiolabeling. As part of its core activity the Radiopharmacy also develops the monoclonal antibody construct conjugation methodologies for the clinical grade materials to be prepared in the cGMP facility for the Phase I trials. Core B will be associated with all three Projects as well as Cores A, C, D and E in this application.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Sta Maria, Naomi S; Barnes, Samuel R; Weist, Michael R et al. (2015) Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells. PLoS One 10:e0142767
Kwok, Cheuk S; Frankel, Paul H; Lopatin, George et al. (2014) Using a single parameter to describe time-activity curves. Cancer Biother Radiopharm 29:83-6
Yazaki, Paul J; Lee, Brian; Channappa, Divya et al. (2013) A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel 26:187-93
Ng, Thomas S C; Wert, David; Sohi, Hargun et al. (2013) Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res 19:2518-27
Specks, Ulrich; Ikle, David; Stone, John H (2013) Induction regimens for ANCA-Associated Vasculitis. N Engl J Med 369:1865-6
Fonge, Humphrey; Leyton, Jeffrey V (2013) Positron emission tomographic imaging of iodine 124 anti-prostate stem cell antigen-engineered antibody fragments in LAPC-9 tumor-bearing severe combined immunodeficiency mice. Mol Imaging 12:191-202
Povoski, Stephen P; Davis, Paul D; Colcher, David et al. (2013) Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics. Expert Rev Mol Diagn 13:315-9
Barat, Bhaswati; Kenanova, Vania E; Olafsen, Tove et al. (2011) Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging. Mol Imaging Biol 13:526-535
Somlo, George; Spielberger, Ricardo; Frankel, Paul et al. (2011) Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res 17:174-82
Gagnon, Pete; Cheung, Chia-Wei; Lepin, Eric J et al. (2010) Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity. Bioprocess Int 8:26-35

Showing the most recent 10 out of 112 publications